C-I3WFCyclarity Therapeutics
cyclodextrins, cholesterol clearance, plaque removal
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-I3WF
C-I3WFC-I3WFcyclodextrins, cholesterol clearance, plaque removal
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cyclarity Therapeutics cyclodextrins, cholesterol clearance, plaque removal
Cyclarity Therapeutics is a US startup developing UDP-003, an engineered cyclodextrin small-molecule candidate aimed at removing 7-ketocholesterol (7KC), a toxic oxidized cholesterol species implicated in atherosclerotic plaque biology. The strongest support is that the program has entered Phase 1 human testing and the company has reported early human PK/PD and safety signals consistent with 7KC excretion, but evidence for plaque regression or clinical benefit remains unproven and is still mostly company-linked or early-stage.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Cyclarity Therapeutics — Translational · Lower middle. Derived deterministically from 7 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic